20/20 Biolabs Inc (AIDX)

$0.61 -0.02 (-3.00%)
Market Cap 8.05M
Revenue (ttm) 2.05M
Net Income (ttm) -3.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -182.44%
Debt to Equity Ratio 0.00
Volume 94,700
Avg Vol 165,608
Day's Range N/A - N/A
Shares Out 12.77M
Stochastic %K 60%
Beta N/A
Analysts Strong Sell
Price Target $5.00

Company Profile

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name t...

Industry: Medical Devices
Sector: Healthcare
Phone: (240) 453-6339
Address:
15810 Gaither Road, Suite 235, Gaithersburg, United States
BigTimePennyStocks
BigTimePennyStocks Aug. 30 at 3:20 PM
Small-Caps with Catalysts this week:👇👇 ( $CIIT, $PMA, $BRNS, $AIDX, $SOAR, etc...) Article in bio... #NASDAQ #NYSE
0 · Reply
focafoca99
focafoca99 Aug. 28 at 10:47 PM
$AIDX postponed its investor webinar to 2 p.m. ET on Sept. 2, after moving it from noon.
0 · Reply
BronnyTheKing
BronnyTheKing Aug. 26 at 1:30 PM
$AIDX — 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity https://finance.yahoo.com/healthcare/articles/20-20-biolabs-host-investor-123100363.html
0 · Reply
TheeVoid
TheeVoid Aug. 21 at 4:34 PM
$AIDX taking off soon
0 · Reply
monte777
monte777 Aug. 21 at 4:08 PM
$AIDX get on Board going ballistic the 🚀
0 · Reply
focafoca99
focafoca99 Aug. 19 at 1:27 PM
$AIDX held its annual meeting, electing six directors and approving an equity incentive plan.
0 · Reply
Lonestardom
Lonestardom Aug. 17 at 1:31 PM
$AIDX — 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level https://finance.yahoo.com/healthcare/articles/20-20-biolabs-reports-second-123100859.html
0 · Reply
STACKD0E
STACKD0E Aug. 17 at 12:53 PM
$AIDX $DRMA $CSAI $NCTY đź‘€
0 · Reply
focafoca99
focafoca99 Aug. 17 at 12:46 PM
$AIDX comments on Q2 2026 results, reporting $0.7M revenue, 47% YoY growth, and Series E financing that eliminated convertible note debt.
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 17 at 12:34 PM
$AIDX 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
0 · Reply
Latest News on AIDX
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Aug 28, 2026, 6:26 PM EDT - 6 days ago

20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

Aug 26, 2026, 8:31 AM EDT - 8 days ago

20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

Aug 17, 2026, 8:31 AM EDT - 17 days ago

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour

Jul 30, 2026, 8:31 AM EDT - 5 weeks ago

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

Jul 27, 2026, 4:30 PM EDT - 5 weeks ago

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

Jul 23, 2026, 8:31 AM EDT - 6 weeks ago

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

Jul 9, 2026, 4:01 PM EDT - 1 month ago

20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

Jun 22, 2026, 4:45 PM EDT - 2 months ago

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

May 27, 2026, 8:31 AM EDT - 3 months ago

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

20/20 BioLabs develops contingency plans to establish Ebola, Hantavirus

2026-05-22T12:48:59.000Z - 3 months ago

20/20 BioLabs develops contingency plans to establish Ebola, Hantavirus

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

May 22, 2026, 8:31 AM EDT - 3 months ago

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

May 20, 2026, 4:05 PM EDT - 3 months ago

20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026

May 14, 2026, 8:31 AM EDT - 3 months ago

20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026

20/20 BioLabs enters licensing agreement with University of South Carolina

2026-05-12T14:02:02.000Z - 3 months ago

20/20 BioLabs enters licensing agreement with University of South Carolina

20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina

May 12, 2026, 8:31 AM EDT - 3 months ago

20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina

20/20 BioLabs initiated with a Buy at Maxim

2026-05-11T15:28:33.000Z - 3 months ago

20/20 BioLabs initiated with a Buy at Maxim

20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform

Apr 7, 2026, 8:31 AM EDT - 4 months ago

20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform

20/20 BioLabs files to sell 10.1M shares of common stock for holders

2026-04-06T21:35:08.000Z - 5 months ago

20/20 BioLabs files to sell 10.1M shares of common stock for holders

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

Mar 31, 2026, 4:57 PM EDT - 5 months ago

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

20/20 BioLabs announces grants for Maryland fire departments to procure OneTest

2026-03-27T12:57:40.000Z - 5 months ago

20/20 BioLabs announces grants for Maryland fire departments to procure OneTest

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest ™ Multi-Cancer Early Detection Blood Test

Mar 27, 2026, 8:31 AM EDT - 5 months ago

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest ™ Multi-Cancer Early Detection Blood Test

20/20 BioLabs enters exclusive technology license, access agreement with Rokit

2026-03-24T12:46:06.000Z - 5 months ago

20/20 BioLabs enters exclusive technology license, access agreement with Rokit

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

Mar 24, 2026, 8:31 AM EDT - 5 months ago

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

20/20 BioLabs provides update on protein biomarket technology for MCED

2026-03-12T12:50:29.000Z - 5 months ago

20/20 BioLabs provides update on protein biomarket technology for MCED

20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies

Mar 12, 2026, 8:31 AM EDT - 5 months ago

20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies

20/20 Biolabs, Inc. Common Stock trading resumes

2026-02-25T15:10:13.000Z - 6 months ago

20/20 Biolabs, Inc. Common Stock trading resumes

20/20 Biolabs, Inc. Common Stock trading halted, volatility trading pause

2026-02-25T15:00:36.000Z - 6 months ago

20/20 Biolabs, Inc. Common Stock trading halted, volatility trading pause

20/20 BioLabs announces launch, commercial availability of OneTest

2026-02-25T13:54:37.000Z - 6 months ago

20/20 BioLabs announces launch, commercial availability of OneTest

20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities

Feb 25, 2026, 8:31 AM EST - 6 months ago

20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities

20/20 Biolabs, Inc. Common Stock trading resumes

2026-02-23T14:40:15.000Z - 6 months ago

20/20 Biolabs, Inc. Common Stock trading resumes

20/20 Biolabs, Inc. Common Stock trading halted, volatility trading pause

2026-02-23T14:35:36.000Z - 6 months ago

20/20 Biolabs, Inc. Common Stock trading halted, volatility trading pause

20/20 Biolabs IPO Registration Document (S-1)

Dec 12, 2025, 5:19 PM EST - 8 months ago

20/20 Biolabs IPO Registration Document (S-1)

BigTimePennyStocks
BigTimePennyStocks Aug. 30 at 3:20 PM
Small-Caps with Catalysts this week:👇👇 ( $CIIT, $PMA, $BRNS, $AIDX, $SOAR, etc...) Article in bio... #NASDAQ #NYSE
0 · Reply
focafoca99
focafoca99 Aug. 28 at 10:47 PM
$AIDX postponed its investor webinar to 2 p.m. ET on Sept. 2, after moving it from noon.
0 · Reply
BronnyTheKing
BronnyTheKing Aug. 26 at 1:30 PM
$AIDX — 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity https://finance.yahoo.com/healthcare/articles/20-20-biolabs-host-investor-123100363.html
0 · Reply
TheeVoid
TheeVoid Aug. 21 at 4:34 PM
$AIDX taking off soon
0 · Reply
monte777
monte777 Aug. 21 at 4:08 PM
$AIDX get on Board going ballistic the 🚀
0 · Reply
focafoca99
focafoca99 Aug. 19 at 1:27 PM
$AIDX held its annual meeting, electing six directors and approving an equity incentive plan.
0 · Reply
Lonestardom
Lonestardom Aug. 17 at 1:31 PM
$AIDX — 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level https://finance.yahoo.com/healthcare/articles/20-20-biolabs-reports-second-123100859.html
0 · Reply
STACKD0E
STACKD0E Aug. 17 at 12:53 PM
$AIDX $DRMA $CSAI $NCTY đź‘€
0 · Reply
focafoca99
focafoca99 Aug. 17 at 12:46 PM
$AIDX comments on Q2 2026 results, reporting $0.7M revenue, 47% YoY growth, and Series E financing that eliminated convertible note debt.
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 17 at 12:34 PM
$AIDX 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
0 · Reply
Gairbear
Gairbear Aug. 13 at 6:48 PM
$AIDX building up for a run
0 · Reply
Quest13
Quest13 Aug. 12 at 6:37 PM
$AIDX Loading. Expecting a pump.
0 · Reply
MarketMaven59
MarketMaven59 Jul. 28 at 1:30 PM
$AIDX — 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy https://finance.yahoo.com/healthcare/articles/20-20-biolabs-participates-bio-203000683.html
0 · Reply
showmethemoney75
showmethemoney75 Jul. 28 at 1:26 PM
$AIDX They have diluted the crap out of this
0 · Reply
showmethemoney75
showmethemoney75 Jul. 28 at 1:26 PM
$AIDX Looks like .30s today
0 · Reply
Huskersnsaints
Huskersnsaints Jul. 28 at 8:31 AM
$AIDX another positive PR And this will be trading below .40
0 · Reply
Stocks4Sophia
Stocks4Sophia Jul. 23 at 1:31 PM
$AIDX — 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock https://finance.yahoo.com/healthcare/articles/20-20-biolabs-announces-standstill-123100857.html
0 · Reply
RalphyFields
RalphyFields Jul. 10 at 1:30 PM
$AIDX — 20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth https://finance.yahoo.com/healthcare/articles/20-20-biolabs-highlights-investor-200100817.html
0 · Reply
Lyn30
Lyn30 Jul. 6 at 5:55 PM
$AIDX this should run huge imo As usual all may come with rocket and I may sell at that time . Analyst pt $5 Float 10M U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts 20/20 Biolabs' OneTest Multi-Cancer Early Detection Blood Test Selected As Part Of Firefighter Cancer Screening Initiative For State Of Vermont In Partnership With National Diagnostic Services
0 · Reply
Lyn30
Lyn30 Jul. 6 at 4:58 PM
$AIDX Float 10M 52 weeks high $50 It may run soon🚀🚀🚀🚀
0 · Reply
TradPoof
TradPoof Jul. 6 at 12:26 PM
$AIDX đź‘€ potential đź’Ż% from here. Pending news to drop. Grab a bag đź’°
0 · Reply